Head and neck squamous cell carcinoma (HNSCC) · line 1 · EXTREME (cetuximab + cisplatin/carboplatin + 5-FU; HNSCC R/M, 1L)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | standard |
| Linked regimen | REG-EXTREME-HNSCC |
| ID | IND-HNSCC-RM-1L-EXTREME |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-30 | pending_clinical_signoff |
| Diseases | DIS-HNSCC |
| Sources | SRC-ESMO-HNSCC-2020 SRC-EXTREME-VERMORKEN-2008 SRC-NCCN-HNSCC-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. Standard-track 1L option for R/M SCCHN, especially CPS <1 or IO-contraindicated. Surfaced by curated case patient_hnscc_extreme_cetux_platin_5fu.json (KB drift note: ALGO-HNSCC-RM-1L explicitly noted "CPS <1 R/M HNSCC ideally routes to EXTREME ... explicit IND-HNSCC-RM-1L-EXTREME is deferred to a follow-up content session"). Algorithm wiring (EXTREME branch for CPS <1 + IO-contraindicated) is engine work and out of scope.
Used By
Algorithms
ALGO-HNSCC-RM-1L- ALGO-HNSCC-RM-1L
Indication
IND-LARYNGEAL-RM-1L-EXTREME- IND-LARYNGEAL-RM-1L-EXTREME